Breaking News Instant updates and real-time market news.

TROV

Trovagene

$3.10

0.1 (3.33%)

08:05
11/28/16
11/28
08:05
11/28/16
08:05

Trovagene says PCM technology yields significantly greater detection sensitivity

Trovagene announced that the use of their Precision Cancer Monitoring technology for both urine and plasma EGFR mutation testing yielded significantly greater detection sensitivity than tissue testing alone. Data will be presented at the 17th World Conference on Lung Cancer, December 4-7 in Vienna, Austria. Trovagene's abstract entitled, A Highly Sensitive Next Generation Sequencing Platform for Detection of NSCLC EGFR T790M in Urine and Plasma, was selected for an oral presentation. This presentation will include data showing a 95% overall detection rate of EGFR T790M by combined urine and plasma versus 83% detection by tissue testing. Additionally, the detection rate in intrathoracic lung cancer disease, in the absence of distant metastases, was an unprecedented 93%. This data further validates the high sensitivity of Trovagene's, Trovera urine and blood liquid biopsy test to identify the EGFR T790M resistance mutation in patients with late-stage non-small cell lung cancer progressing on 1st or 2nd generation TKIs. Two additional abstracts, one a case series, focus on recent work demonstrating that EGFR ctDNA can serve as an early indicator of therapeutic response, providing valuable information particularly in the setting of late-stage patients treated with experimental therapeutics or in patients progressing on therapy. The dynamic changes in ctDNA EGFR systemic load observed in this case series is consistent with previous findings. A fourth poster presentation will feature cost of care analysis data demonstrating the value of a urine testing strategy as a dominant care pathway compared to a tissue testing strategy by saving costs and improving progression-free and overall survival for patients with non-small cell lung cancer.

  • 29

    Nov

TROV Trovagene
$3.10

0.1 (3.33%)

07/07/16
PIPR
07/07/16
NO CHANGE
PIPR
New FDA recommendation positive for lab companies, says Piper Jaffray
Piper Jaffray analyst William Quirk says that the FDA has issued draft guidance to streamline its approval process for next-generation sequencing, or NGS, germline tests, which could be a substitute for a Premarket Notification or 510k. The analyst believes streamlined regulatory approaches for NGS tests are a positive for labs with NGS laboratory-developed tests such as CareDx (CDNA), Quest Diagnostics (DGX), Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA), Oxford Immunotec (OXFD), Sequenom (SQNM), Trovagene (TROV), and Veracyte (VCYT).
08/08/16
CANT
08/08/16
UPGRADE
CANT
Buy
Trovagene upgraded to Buy from Hold at Cantor
08/08/16
CANT
08/08/16
UPGRADE
Target $7
CANT
Buy
Trovagene upgraded to Buy with $7 target at Cantor
Cantor Fitzgerald analyst Bryan Brokmeier upgraded Trovagene to Buy from Hold citing the company's accelerating clinical business. In Q2, the company increased the number of physicians on the platform to approximately 700 physicians from 550 in Q1, Brokmeier tells investors in a research note. He points out that Trovagene is also targeting new biopharma collaborations. The analyst raised his price target for the shares to $7 from $5.
09/30/16
CANT
09/30/16
NO CHANGE
CANT
Trovagene outlook has improved, says Cantor
After meeting with Trovagene's management, Cantor analyst Bryan Brokmeier is more upbeat on the stock. He says that the company's new strategy :"significantly reduces" its cash needs, provides it with multiple potential positive catalysts and reduces its competition. The analyst keeps an $8 price target and Buy rating on the shares.

TODAY'S FREE FLY STORIES

REED

Reed's

13:05
04/24/17
04/24
13:05
04/24/17
13:05
Earnings
Reed's sees Q1 revenue $8.3M vs. $10M last year »

Reed's said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

13:05
04/24/17
04/24
13:05
04/24/17
13:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD topped…

REED

Reed's

13:03
04/24/17
04/24
13:03
04/24/17
13:03
Hot Stocks
Reed's founder and CEO resigns, becomes Chief Innovation Officer »

Reed's announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

REED

Reed's

13:02
04/24/17
04/24
13:02
04/24/17
13:02
Syndicate
Reed's closes $3.4M private placement »

Reed's announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

BDX

Becton Dickinson

$178.36

-6.93 (-3.74%)

13:00
04/24/17
04/24
13:00
04/24/17
13:00
Upgrade
Becton Dickinson rating change  »

Becton Dickinson upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 04

    May

  • 06

    Jun

JNJ

Johnson & Johnson

$122.72

0.96 (0.79%)

, NVS

Novartis

$74.36

0.955 (1.30%)

12:57
04/24/17
04/24
12:57
04/24/17
12:57
Periodicals
J&J, Novartis, Takeda in talks over Hypermarcas takeover, Reuters says »

Johnson & Johnson…

JNJ

Johnson & Johnson

$122.72

0.96 (0.79%)

NVS

Novartis

$74.36

0.955 (1.30%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.29

0.215 (0.89%)

HYPMY

Hypermarcas

$9.66

0.44 (4.77%)

BBD

Banco Bradesco

$10.17

0.33 (3.35%)

CS

Credit Suisse

$15.16

0.705 (4.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 06

    Jun

  • 26

    Jun

REED

Reed's

12:56
04/24/17
04/24
12:56
04/24/17
12:56
Hot Stocks
Breaking Hot Stocks news story on Reed's »

Reed's trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

, W

Wayfair

$46.66

0.7 (1.52%)

12:55
04/24/17
04/24
12:55
04/24/17
12:55
Periodicals
Amazon hopes to launch furniture seller program, Furniture Today reports »

In a report highlighted…

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

W

Wayfair

$46.66

0.7 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 09

    May

  • 16

    May

  • 17

    May

  • 23

    May

MMM

3M

$193.60

2.1 (1.10%)

12:55
04/24/17
04/24
12:55
04/24/17
12:55
Technical Analysis
3M technical notes before earnings news »

The stock has recently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 31

    May

CAT

Caterpillar

$96.85

2.53 (2.68%)

12:52
04/24/17
04/24
12:52
04/24/17
12:52
Earnings
On The Fly: What to watch in Caterpillar earnings report »

Caterpillar (CAT) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

  • 14

    Jun

MU

Micron

$27.32

-0.64 (-2.29%)

12:51
04/24/17
04/24
12:51
04/24/17
12:51
Options
Bullish sentiment in Micron May 5th options ahead of a company event »

Bullish sentiment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 07

    Jun

AKRX

Akorn

$32.91

-0.09 (-0.27%)

, FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

12:50
04/24/17
04/24
12:50
04/24/17
12:50
Periodicals
Akorn close to buyout deal at $33-$35/share, Reuters reports »

Akorn (AKRX) is near a…

AKRX

Akorn

$32.91

-0.09 (-0.27%)

FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

$89.22

1.23 (1.40%)

12:49
04/24/17
04/24
12:49
04/24/17
12:49
Hot Stocks
Fitch: Mexican regulation could pressure Kansas City Southern »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 09

    May

AKRX

Akorn

$32.91

-0.09 (-0.27%)

, FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

12:47
04/24/17
04/24
12:47
04/24/17
12:47
Periodicals
Breaking Periodicals news story on Akorn, Fresenius SE »

Sources: Fresenius could…

AKRX

Akorn

$32.91

-0.09 (-0.27%)

FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRX

Akorn

$32.91

-0.09 (-0.27%)

, FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

12:44
04/24/17
04/24
12:44
04/24/17
12:44
Periodicals
Breaking Periodicals news story on Akorn, Fresenius SE »

Fresenius nears deal to…

AKRX

Akorn

$32.91

-0.09 (-0.27%)

FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$70.71

2 (2.91%)

12:41
04/24/17
04/24
12:41
04/24/17
12:41
Options
Notable call write in Comerica as shares rally »

Notable call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CRHM

CRH Medical

$5.75

-1.6 (-21.77%)

12:40
04/24/17
04/24
12:40
04/24/17
12:40
Recommendations
CRH Medical analyst commentary  »

Cantor discusses recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

GOOG

Alphabet

$843.19

1.54 (0.18%)

, GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

12:36
04/24/17
04/24
12:36
04/24/17
12:36
Hot Stocks
Google adds TV to 'DoubleClick' ad buying platform »

Google announced in its…

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 22

    May

ORAN

Orange SA

$15.98

0.935 (6.22%)

, FB

Facebook

$143.68

-0.12 (-0.08%)

12:36
04/24/17
04/24
12:36
04/24/17
12:36
Hot Stocks
Orange partners with Facebook to launch startup accelerator »

Orange is working with…

ORAN

Orange SA

$15.98

0.935 (6.22%)

FB

Facebook

$143.68

-0.12 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

BIIB

Biogen

$272.94

0.48 (0.18%)

12:32
04/24/17
04/24
12:32
04/24/17
12:32
Technical Analysis
Biogen technical remarks ahead of earnings news »

The stock has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 31

    May

XOP

SPDR Oil Exploration and Production Fund

$35.41

0.3 (0.85%)

12:31
04/24/17
04/24
12:31
04/24/17
12:31
Options
Defensive option play in SPDR Oil Exploration and Production ETF »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$116.82

-1.9 (-1.60%)

12:26
04/24/17
04/24
12:26
04/24/17
12:26
Options
Alexion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 23

    Oct

MCK

McKesson

$136.22

0.3 (0.22%)

, TSRO

Tesaro

$136.01

-3 (-2.16%)

12:26
04/24/17
04/24
12:26
04/24/17
12:26
Hot Stocks
Biologics Inc says selected as specialty pharmacy provider for Tesaro's Zejula »

Biologics Inc, a McKesson…

MCK

McKesson

$136.22

0.3 (0.22%)

TSRO

Tesaro

$136.01

-3 (-2.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

  • 30

    Jun

AGN

Allergan

$238.06

1.71 (0.72%)

, BIIB

Biogen

$272.94

0.48 (0.18%)

12:25
04/24/17
04/24
12:25
04/24/17
12:25
Conference/Events
Piper Jaffray biopharma analysts hold an analyst/industry conference call »

Biopharmaceuticals…

AGN

Allergan

$238.06

1.71 (0.72%)

BIIB

Biogen

$272.94

0.48 (0.18%)

CARA

Cara Therapeutics

$16.53

-0.56 (-3.28%)

COLL

Collegium Pharmaceutical

$10.24

0.19 (1.89%)

EGLT

Egalet

$4.24

0.02 (0.47%)

ENDP

Endo

$10.29

-0.19 (-1.81%)

NKTR

Nektar

$18.37

-0.76 (-3.97%)

PFE

Pfizer

$33.82

0.18 (0.54%)

TEVA

Teva

$31.81

0.68 (2.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 07

    May

  • 09

    May

  • 11

    May

  • 31

    May

  • 06

    Jun

  • 08

    Jun

  • 27

    Aug

  • 30

    Aug

SNAP

Snap

$21.19

0.26 (1.24%)

, YHOO

Yahoo

$47.52

-0.15 (-0.31%)

12:17
04/24/17
04/24
12:17
04/24/17
12:17
Hot Stocks
Yahoo discloses stake in Snap »

In the "Schedule of…

SNAP

Snap

$21.19

0.26 (1.24%)

YHOO

Yahoo

$47.52

-0.15 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.